Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
OralvacB2MPL · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | 4 consecutive groups, dose escalation |
| 2 | PLACEBO_COMPARATOR | 4 consecutive groups |
| Name | Type | Description |
|---|---|---|
| OralvacB2MPL | BIOLOGICAL | Comparison of different dosages of drug |
Inclusion Criteria: * Male or female subjects, between 18 and 65 years. * BMI 18 - 32 kg/m². * Positive skin prick test (wheal\>4mm) with grasses pollen allergen extract. * Specific IgE to grass pollen allergens by RAST (or equivalent test) ≥ class 2. * Women of childbearing potential must be using...
OralvacB2MPL is an investigational monoclonal antibody being developed for Type I Hypersensitivity, a condition involving allergic reactions. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied for its safety, immunological effects, and efficacy in this indication.
OralvacB2MPL is being developed by cbdMD, Inc., a company publicly traded under the ticker symbol YCBD. The company is conducting clinical research on this investigational monoclonal antibody for the treatment of Type I Hypersensitivity.
OralvacB2MPL is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or other regulatory agencies. The drug is being studied in a completed Phase 1 trial to evaluate its safety, immunological effects, and efficacy in patients with Type I Hypersensitivity.
OralvacB2MPL has one completed Phase 1 clinical trial registered under NCT00241410. The trial, titled "Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen," enrolled 86 participants in Germany. The study was randomized, double-blind, and placebo-controlled, and included healthy volunteers aged 18 years and older.
Yes, OralvacB2MPL is a monoclonal antibody. It is being developed as an investigational treatment for Type I Hypersensitivity. The drug is currently in Phase 1 clinical development, and its safety and efficacy are being evaluated in clinical trials.